Verve Therapeutics Inc Stock Research

Market Summary

USD14.42+0.07

Delayed

0.49%

VERV Stock Price

VERV RSI Chart

VERV Valuation

Market Cap

890.2M

Price/Earnings (Trailing)

-5.66

Price/Sales (Trailing)

458.61

Price/Free Cashflow

-6.57

VERV Price/Sales (Trailing)

VERV Profitability

Return on Equity

-28.57%

Return on Assets

-23.17%

Free Cashflow Yield

-15.23%

VERV Fundamentals

VERV Revenue

Revenue (TTM)

1.9M

VERV Earnings

Earnings (TTM)

-157.4M

Earnings Y/Y

-31.11%

Earnings Q/Q

9.08%

Price Action

52 Week Range

10.7043.00

(Low)(High)

Last 7 days

-14.8%

Last 30 days

-27.9%

Last 90 days

-20.8%

Trailing 12 Months

-40.0%

VERV Financial Health

Current Ratio

16.05

VERV Investor Care

Shares Dilution (1Y)

27.25%

Diluted EPS (TTM)

-2.91

Financials for Verve Therapeutics

Income Statement (Last 12 Months)
Description	(%) Q/Q	2022Q4	2022Q3	2021Q4	2020Q4
Revenue	-47.8%	1,941,000	3,716,000			-
Operating Expenses	10.7%	167,628,000	151,446,000	87,067,000	-	-
S&GA Expenses	14.8%	37,533,000	32,695,000	18,865,000	-	-
R&D Expenses	9.6%	130,095,000	118,751,000	68,202,000	-	-
Net Income	-6.6%	-157,387,000	-147,639,000	-120,314,000	-	-
Net Income Margin	-104.1%	-81.09	-39.73	-	-	-
Free Cahsflow	-7.0%	-135,564,000	-126,728,000	-	-	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	0.9%	679	673	324	349	384
Current Assets	0.3%	563	562	299	329	367
Cash Equivalents	-56.6%	120	277	73.00	91.00	64.00
Net PPE	23.9%	19.00	15.00	12.00	11.00	7.00
Liabilities	2.3%	128	125	28.00	18.00	27.00
Current Liabilities	20.9%	35.00	29.00	26.00	15.00	22.00
Shareholder's Equity	0.5%	551	548	296	331	357
Retained Earnings	-13.6%	-344	-303	-257	-217	-186
Additional Paid-In Capital	5.1%	896	852	555	549	544
Accumulated Depreciation	20.5%	4.00	3.00	3.00	2.00	-
Shares Outstanding	2.1%	62.00	60.00	49.00	49.00	49.00

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	-4.1%	-122	-117	-109	-96.25	-77.88
Share Based Compensation	21.3%	22.00	19.00	15.00	11.00	7.00
Cashflow From Investing	-249.5%	-155	-44.63	-201	-190	-239
Cashflow From Financing	13.2%	329	291	1.00	284	377

Risks for VERV

What is the probability of a big loss on VERV?

85.0%

Probability that Verve Therapeutics stock will be more than 20% underwater in next one year

85.0%

Probability that Verve Therapeutics stock will be more than 30% underwater in next one year.

82.8%

Probability that Verve Therapeutics stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does VERV drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Verve Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for VERV

Cumulative Returns on VERV

Which funds bought or sold VERV recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-02-28	Voya Investment Management LLC	added	3.45	-248,919	347,081	-%
2023-02-21	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	new	-	77.00	77.00	-%
2023-02-16	HARBOUR INVESTMENTS, INC.	new	-	19,350	19,350	-%
2023-02-15	MetLife Investment Management, LLC	unchanged	-	-370,500	477,500	-%
2023-02-15	JANE STREET GROUP, LLC	new	-	267,340	267,340	-%
2023-02-15	McIlrath & Eck, LLC	unchanged	-	-1,549	1,451	-%
2023-02-15	LAZARD ASSET MANAGEMENT LLC	reduced	-21.5	-37,000	27,000	-%
2023-02-15	NOMURA HOLDINGS INC	new	-	634,000	634,000	-%
2023-02-15	Metropolitan Life Insurance Co/NY	unchanged	-	-41,859	54,141	-%
2023-02-15	Highlander Capital Management, LLC	unchanged	-	-7,000	10,000	-%

Latest Funds Activity

Are funds buying VERV calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own VERV

No. of Funds

Verve Therapeutics News

Schedule 13G FIlings of Verve Therapeutics

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	singer james r	8.1%	5e+06	SC 13G/A
Feb 14, 2023	casdin capital, llc	3.7%	2,290,571	SC 13G/A
Feb 13, 2023	arch venture fund x, l.p.	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	6.19%	3,812,024	SC 13G
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 07, 2023	state street corp	7.26%	4,471,049	SC 13G
Feb 06, 2023	wellington management group llp	1.39%	859,102	SC 13G/A
Feb 14, 2022	gv 2017, l.p.	13.12%	6,320,905	SC 13G
Feb 14, 2022	casdin capital, llc	6.5%	3,138,167	SC 13G/A
Feb 09, 2022	fmr llc	-	0	SC 13G/A

VERV Fair Value

Recent SEC filings of Verve Therapeutics

View All Filings

Date Filed	Form Type	Document
Mar 02, 2023	10-K	Annual Report
Mar 02, 2023	8-K	Current Report
Mar 02, 2023	S-8	Employee Benefits Plan
Feb 23, 2023	3	Insider Trading
Feb 17, 2023	8-K	Current Report
Feb 16, 2023	4	Insider Trading
Feb 16, 2023	4	Insider Trading
Feb 16, 2023	4	Insider Trading
Feb 16, 2023	4	Insider Trading
Feb 16, 2023	4	Insider Trading

Latest Insider Trading transactions for VERV

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2022-12-14	Bellinger Andrew	acquired	103,320	2.87	36,000	cso & cmo
2022-12-01	Bellinger Andrew	sold	-19,851	22.95	-865	cso & cmo
2022-11-29	Dorval Allison	acquired	-	-	1,875	chief financial officer
2022-11-29	Dorval Allison	sold	-12,243	22.1	-554	chief financial officer
2022-11-04	GV 2017 GP, L.L.C.	sold	-1,512,810	31.1386	-48,583	-
2022-11-04	Yeshwant Krishna	sold	-1,512,810	31.1386	-48,583	-
2022-11-04	Yeshwant Krishna	sold	-	-	-48,583	-
2022-11-04	GV 2017 GP, L.L.C.	sold	-1,512,800	31.1386	-48,583	-
2022-11-04	GV 2017 GP, L.L.C.	sold	-	-	-48,583	-
2022-11-03	GV 2017 GP, L.L.C.	sold	-	-	-49,569	-

About Verve Therapeutics

Sekar Kathiresan

www.vervetx.com

110

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

VERV Income Statement

2022-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Collaborations revenue	$ 1,941	$ 0	$ 0
Operating expenses:
Research and development	130,095	68,202	35,371
General and administrative	37,533	18,865	5,256
Total operating expenses	167,628	87,067	40,627
Loss from operations	(165,687)	(87,067)	(40,627)
Other income (expense):
Change in fair value of preferred stock tranche liability	0	0	2,507
Change in fair value of antidilution rights liability	0	(25,574)	(5,359)
Change in fair value of success payment liability	1,486	(7,815)	(2,387)
Interest and other income, net	6,867	142	162
Total other expense, net	8,353	(33,247)	(5,077)
Loss before provision for income taxes	(157,334)	(120,314)	(45,704)
Provision for income taxes	53	0	0
Net loss	$ (157,387)	$ (120,314)	$ (45,704)
Net loss per common share attributable to common stockholders, basic	$ (2.91)	$ (4.48)	$ (20.31)
Net loss per common share attributable to common stockholders, diluted	$ (2.91)	$ (4.48)	$ (20.31)
Weighted-average common shares used in net loss per share attributable to common stockholders, basic	54,023,653	26,872,036	2,250,093
Weighted-average common shares used in net loss per share attributable to common stockholders, diluted	54,023,653	26,872,036	2,250,093
Comprehensive Loss:
Net loss	$ (157,387)	$ (120,314)	$ (45,704)
Other comprehensive loss:
Unrealized loss on marketable securities	(466)	(236)	(1)
Comprehensive loss	$ (157,853)	$ (120,550)	$ (45,705)

VERV Balance Sheet

2022-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 115,412	$ 64,330
Marketable securities	439,396	296,112
Collaboration receivable	1,012	0
Prepaid expenses and other current assets	7,339	6,686
Total current assets	563,159	367,128
Property and equipment, net	18,778	7,224
Restricted cash	4,824	5,237
Operating lease right-of-use assets	91,877	1,839
Other long term assets	585	2,696
Total assets	679,223	384,124
Current liabilities:
Accounts payable	2,424	7,077
Accrued expenses	20,767	12,992
Operating lease obligations, current portion	11,904	1,955
Total current liabilities	35,095	22,024
Long-term lease liability	70,014	0
Deferred revenue, non-current	20,014
Success payment liability	2,885	4,371
Other long term liabilities	283	377
Total liabilities	128,291	26,772
Commitments and contingencies (See Note 7 and 8)
Convertible preferred stock (See Note 10)	0	0
Stockholders’ equtiy (deficit):
Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and oustanding	0	0
Common stock, $0.001 par value; 200,000,000 and 255,000,000 shares authorized at December 31, 2022 and 2021, respectively, 61,730,816 and 48,511,735 shares issued at December 31, 2022 and 2021, respectively; 61,730,816 and 48,511,735 shares outstanding at December 31, 2022 and 2021, respectively	62	49
Additional paid-in capital	895,801	544,381
Accumulated other comprehensive (loss) income	(694)	(228)
Accumulated deficit	(344,237)	(186,850)
Total stockholders’ equity (deficit)	550,932	357,352
Total liabilities, and stockholders' equity	$ 679,223	$ 384,124